Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

These participants were randomly assigned to treatment with either a combination of the HER2 inhibitors trastuzumab (Herceptin ®) and pertuzumab (Perjeta ®) (TP) every three weeks or a standard ...

For Perjeta, the survival rate was 56 months versus 40 months seen with only Herceptin and chemotherapy-based treatment," said Dr Sudeep Gupta of TMC. "If patients can afford, we recommend this drug." ...

Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

In addition, with the launch of Perjeta in 2012, Kadcyla in 2013, and Phesgo (a subcutaneous coformulation of Herceptin and Perjeta) in 2020, Roche has somewhat refreshed its breast cancer franchise.

after a first course of chemotherapy and dual blockade and HER2 blockade with pertuzumab [Perjeta]/trastuzumab [Herceptin], usually treat with the maintenance treatment with pertuzumab/trastuzumab ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...